Walder Wyss advises BioVersys on its Series B Financing Round

Walder Wyss advises BioVersys, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics, on its Series B Financing Round. The financing round amounts to CHF 19 mio. and was subscribed by existing shareholders as well as new investors.

The team was led by Alexander Gutmans (Partner, Transaction/M&A & Venture Capital) and Robert von Rosen (Partner, Transaction/M&A & Venture Capital) and included Ayesha Curmally (Partner, Notary Services), Jessica Aeschbach Flórez (Senior Associate, Transaction/M&A) and Karina Tschon (Associate Transaction/M&A).

FabioAdmin

SHARE